Norway, Feb. 17 -- Lifecare ASA (LIFE), a MedTech company developing next-generation implantable Continuous Glucose Monitoring (CGM) technology, today announces the successful completion of final compliance testing of the electronics used in its implant system, marking a decisive regulatory development.The completed testing has been performed on electronics used in implants manufactured under Lifecare's reproducible and quality-controlled production protocol - the same structured batch currently deployed in the ongoing longevity study (LFC-SEN-002) and planned deployed in Lifecares First-In-Human study (pending approval) and for the commercial veterinary version.Compliance testing of electronics used in the reproducible manufacturing batch ...